Top Story
“Take a Breath” on the Specialty Drug Pricing Issue?
For Tom Norton, watching the latest volleys fly in the ongoing specialty drug pricing wars makes one wonder: Is it possible that all involved couldn't just step back and take a breath?
...Read more
Regulatory
Pharma Gains Marketing Flexibility, Loses Exclusivities in Revised “Cures” Proposal
The 21st Century Cures initiative includes provisions for more flexibility in drug communications and product development, making it easier for pharma companies to distribute journal articles and medical textbooks to physicians. But the legislation drops a number of earlier provisions that provided added exclusivity for certain new therapies, writes Jill Wechsler
...Read more
Biosimilars: Litigation and Patent Challenges to Come
The risks involved with patent suits may become a bit more undesirable, thanks to new legislation aimed at deterring unreasonable patent suits. A senate bill introduced in late April 2015 will make it more difficult for so-called "patent trolls," to bring patent suits to court ...Read more
You probably spend more on rebates every year than marketing. But you scrutinize your marketing investments much more carefully than you optimize your rebates. There is a real opportunity to increase your profits with better rebate contract management.
 Read this article
to learn how.
Event
iPharma 2015 — CBI's Marketing Innovation Summit | May 14–15, New York, NY
Tap into the latest trends in life sciences technology, content and communications – only at iPharma 2015! Inspirational keynotes Jeremy Bloom and Rand Fishkin anchor the meeting along with industry leaders representing Novartis, GSK, Alcon, Boehringer, Lundbeck, GE Healthcare, BMS, Shire, Takeda, Biogen, Purdue, J&J, Pfizer, Bayer and many more! Plus, don't miss PharmExec's prestigious Brand of the Year unveiling during a special awards ceremony.
Register now or learn more
Hiding in Plain Slight
Co-pay as the key to Patient engagement?
Live Webcast: Thursday, May 21th, 2015 at 2:00 PM
How CoPay Programs can Increase Patient Engagement - What Your CoPay Program Should be Delivering for you.
 Register for free
Strategy
Opposites Attract: Pairing R&D and Commercial Teams
Without insights from Commercial functions at an earlier stage of drug development, R&D teams can miss crucial information that can cost pharma companies billions. Meike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice
...Read more
Rare Disease Roundtable
What's Real in Rare Disease
Pharm Exec convened an expert panel on rare disease to highlight the challenges of serving expectant patients in this uniquely complex market access environment
...Read more
|
|
|
 //Keryx Biopharmaceuticals (Boston, MA) announced the completion of its previously announced transition of the CEO role from Ron Bentsur to Greg Madison. //Nuo Therapeutics (Gaithersburg, MD) announced that David Jorden, current Executive Chairman of the company's Board of Directors, has been appointed Acting Chief Financial Officer, effective May 24, 2015. //AmpliPhi BioSciences Corporation (Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia) appointed Scott Salka as its new CEO. //ZS Pharma (Redwood City, CA) appointed Kimberly J. Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health, to its Board of Directors. // |
|
